期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 102, 期 3, 页码 405-419出版社
WILEY
DOI: 10.1002/cpt.729
关键词
-
资金
- National Institutes of Health
- National Kidney Foundation
- Amgen
- Pharmalink
- Gilead Sciences
- Siemens
- Otsuka
Acute and chronic kidney diseases affect pharmacokinetics and pharmacodynamics. There has been substantial progress in the past 20 years in the use of glomerular filtration rate (GFR) estimating equations. In principle, use of a single equation for each filtration marker (creatinine, cystatin C, or the combination) for detection, evaluation, andmanagement of kidney disease and for drug development and dosing would facilitate clinical practice. We review the principles for assessment of GFR, provide historical perspectives and updates regarding use of GFR estimating equations, including assay methods for filtrationmarkers, performance of estimating equations, and recommendations by clinical practice guideline groups and regulatory agencies. We conclude that it is time to change fromrigid adherence to the use of the Cockcroft-Gault equation for use in drug development and drug dosing to themore accurate and more widely used Modification of Diet in Renal Disease (MDRD) study and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据